当前位置： SCI文献检索 > LEUKEMIA RESEARCH期刊下所有文献 > Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

Abstract：

:Semenogelin (SEMG) I is a Cancer-Testis (CT) antigen that we have found to be expressed in myeloma cells. In this study, we set out to determine whether the expression of SEMG I could be upregulated pharmacologically. We found that SEMG I expression in myeloma cells can be upregulated by 5-azacytidine, IL-4 and IL-6. The mechanisms of SEMG I gene upregulation by 5-azacytidine is unclear since there was no correlation between the methylation of the single CpG dinucleotide at position -11 and SEMG I expression. Both IL-4 and IL-6 appeared to enhance SEMG I expression through increasing its promoter function.

journal_name

Leuk Res

journal_title

Leukemia research

authors

Zhang Y,Wang Z,Zhang J,Farmer B,Lim SH

doi

10.1016/j.leukres.2008.03.036

subject

Has Abstract

pub_date

2008-12-01 00:00:00

pages

1889-94

issue

12

eissn

0145-2126

issn

1873-5835

pii

S0145-2126(08)00177-X

journal_volume

32

pub_type

杂志文章

相关文献

LEUKEMIA RESEARCH文献大全
  • Variations of the phosphorylation of 1-beta-D-arabinofuranosylcytosine (ARA-C) in human myeloid leukemic cells related to the cell cycle.

    abstract：:Bone marrow cells of five patients with acute myeloid leukemia were fractionated by means of counterflow centrifugation (elutriation). The different fractions were enriched with cells belonging to subsequent stages of the cell cycle. Cytokinetic evaluation of these cell fractions was performed by [3H]thymidine autorad...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(82)90031-5

    authors： Vierwinden G,Drenthe-Schonk AM,Plas AM,Linssen PC,Pennings AH,Holdrinet RS,van Egmond J,Wessels JM,Haanen CA

    更新日期：1982-01-01 00:00:00

  • Src family kinases promote AML cell survival through activation of signal transducers and activators of transcription (STAT).

    abstract：:We investigated the role of Src family kinases (SFKs) in the regulation of STAT activation in myeloid leukemia cells. Two of 6 AML cell lines displayed constitutive STAT5 activation, whereas four cell lines had constitutive SFK activity. Treatment with the SFK inhibitors suppressed STAT5 activation and decreased viabi...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.11.032

    authors： Ozawa Y,Williams AH,Estes ML,Matsushita N,Boschelli F,Jove R,List AF

    更新日期：2008-06-01 00:00:00

  • Mixed myelodysplastic and myeloproliferative syndromes.

    abstract：:Aplastic anemia, myelodysplastic syndromes (MDS) and chronic myeloproliferative diseases (MPD) are stem cell disorders. There is no clear-cut demarcation of them. Hypoplastic MDS displays features of aplastic anemia and MDS, on the other side mixed myelodysplastic and myeloproliferative syndromes (MDS-MPS) develop. In...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/0145-2126(96)00028-8

    authors： Neuwirtová R,Mociková K,Musilová J,Jelínek J,Havlícek F,Michalová K,Adamkov M

    更新日期：1996-09-01 00:00:00

  • Intensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine.

    abstract：:Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1016/s0145-2126(96)00116-6

    authors： Ruutu T,Hänninen A,Järventie G,Koistinen P,Koivunen E,Kätkä K,Nousiainen T,Oksanen K,Pelliniemi TT,Remes K,Timonen T,Volin L,Elonen E

    更新日期：1997-02-01 00:00:00

  • Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.

    abstract：:Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iro...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2017.01.033

    authors： Lyons RM,Marek BJ,Paley C,Esposito J,McNamara K,Richards PD,DiBella N,Garcia-Manero G

    更新日期：2017-05-01 00:00:00

  • Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice.

    abstract：:Osteogenic growth peptide (OGP) increases blood and bone marrow cellularity in mice, and enhances engraftment of bone marrow transplant. Carboxy-terminal pentapeptide (OGP10-14) holds several properties of full-length polypeptide. We evaluated whether synthetic OGP-derived pentapeptide (sOGP10-14) has some activity on...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00091-1

    authors： Fazzi R,Testi R,Trasciatti S,Galimberti S,Rosini S,Piras F,L'Abbate G,Conte A,Petrini M

    更新日期：2002-01-01 00:00:00

  • WITHDRAWN: The effect of dihydroartemisinin on TfR and VEGF expression in iron overload human myeloid leukemia K562 cells.

    abstract：:This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy. ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2009.01.006

    authors： Zengwang,Zhou HJ,Li A,Zhang JL

    更新日期：2009-02-20 00:00:00

  • Levels of CAF7 (CD98) expression correlate with the complete remission duration in childhood acute leukemia.

    abstract：:The levels of expression of the activation antigen CD98 were studied by mAB CAF7 in 51 newly diagnosed consecutive cases of childhood acute lymphoblastic leukemia aged from 1 to 13 years. The mean follow-up was 8 months. A wide range of CAF7 expression was observed, the highest mean fluorescence intensity exceeding th...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(95)00114-x

    authors： Taskov H,Pashov A,ffmitrova E,Yordanova M,Serbinova M

    更新日期：1996-01-01 00:00:00

  • Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death.

    abstract：:We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2013.05.007

    authors： Altman JK,Rademaker A,Cull E,Weitner BB,Ofran Y,Rosenblat TL,Haidau A,Park JH,Ram SL,Orsini JM Jr,Sandhu S,Catchatourian R,Trifilio SM,Adel NG,Frankfurt O,Stein EM,Mallios G,Deblasio T,Jurcic JG,Nimer S,Peterson L

    更新日期：2013-09-01 00:00:00

  • Refractory macrocytic anemias in patients with clonal hematopoietic disorders and isolated mutations of the spliceosome gene ZRSR2.

    abstract：:Although mutations in RNA splicing genes occur frequently in patients with clonal cytopenias of unknown significance (CCUS) and myelodysplastic syndromes (MDS), very often additional common myeloid gene driver mutations are present at diagnosis. Thus, the clinical significance of isolated mutations in the most commonl...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2017.09.002

    authors： Fleischman RA,Stockton SS,Cogle CR

    更新日期：2017-10-01 00:00:00

  • Haemopoietic stem cell: a new concept.

    abstract：:It is generally accepted that morphologically recognizable bone marrow (BM) cells are derived from progenitor cells committed to a specific line of haematopoietic differentiation [51]. The origin and morphological identity of such progenitor cells is not yet known and the question, whether there is a single pluripoten...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/0145-2126(85)90130-4

    authors： Islam A

    更新日期：1985-01-01 00:00:00

  • Evaluation of the European LeukemiaNet recommendations for predicting outcomes of patients with acute myeloid leukemia treated in low- and middle-income countries (LMIC): A Brazilian experience.

    abstract：BACKGROUND:Current results regarding treatment outcomes in acute myeloid leukemia (AML) point to significant differences between low- and middle-income countries (LMIC) and high-income countries (HIC). Excluding well-known socioeconomic issues, genetic markers important for prognosis have not been properly incorporated...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2017.07.005

    authors： Benicio MTL,Ribeiro AFT,Américo AD,Furtado FM,Glória AB,Lima AS,Santos SM,Xavier SG,Lucena-Araujo AR,Fagundes EM,Rego EM

    更新日期：2017-09-01 00:00:00

  • Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status.

    abstract：:Hypereosinophilic syndrome (HES) is characterized by sustained non-clonal blood and tissue eosinophilia, leading to end-organ damage. With a molecular/cytogenetic clonality marker, the disease is classified as chronic eosinophilic leukemia (CEL). Efficacy of imatinib mesylate is well established in CEL with FIP1L1-pla...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.10.004

    authors： Jain N,Cortes J,Quintás-Cardama A,Manshouri T,Luthra R,Garcia-Manero G,Kantarjian H,Verstovsek S

    更新日期：2009-06-01 00:00:00

  • Activation of c-Jun N-terminal kinase is essential for oxidative stress-induced Jurkat cell apoptosis by monochloramine.

    abstract：:Leukemic cell apoptosis may be enhanced by appropriate oxidative stress. We report here the mechanism of Jurkat cell apoptosis by monochloramine (NH(2)Cl), a neutrophil-derived oxidant. NH(2)Cl induced caspase-dependent apoptosis, which was preceded by cytochrome c and Smac/Diablo release from mitochondria. Within 10m...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.07.009

    authors： Ogino T,Ozaki M,Hosako M,Omori M,Okada S,Matsukawa A

    更新日期：2009-01-01 00:00:00

  • CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study.

    abstract：:Deletion in chromosome 9p involving the CDKN2A locus (9p21.3) is known in many malignancies. To detect this deletion in adolescent ALL patients we used oligo array CGH and studied 54 patients aged 10-25 years. Deletion rate was 25/54 (46%), of these 19/25 (76%) were homozygous. Small deletions (<200 kb) were found in ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.01.014

    authors： Usvasalo A,Savola S,Räty R,Vettenranta K,Harila-Saari A,Koistinen P,Savolainen ER,Elonen E,Saarinen-Pihkala UM,Knuutila S

    更新日期：2008-08-01 00:00:00

  • Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.

    abstract：:This prospective phase II clinical trial evaluated the effects of single-dose mitoxantrone (36 mg/m2 on day 1) in combination with continuous infusion intermediate-dose cytarabine plus etoposide in 25 patients with refractory or early relapsed acute myeloid leukemia (AML). We compared the results of our current study ...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2008.08.009

    authors： Lee SS,Lee JH,Lee JH,Kim DY,Kim SH,Lim SN,Lee YS,Seol M,Ryu SG,Kang YA,Jang S,Park CJ,Chi HS,Yun SC,Lee KH

    更新日期：2009-04-01 00:00:00

  • Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.

    abstract：:There is a significant need for improved therapeutics in older patients with acute leukemia. Camidanlumab tesirine is an antibody-drug conjugate against CD25, an antigen expressed in several malignancies, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This open-label, dose-escalation an...

    journal_title：Leukemia research

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.leukres.2020.106385

    authors： Goldberg AD,Atallah E,Rizzieri D,Walter RB,Chung KY,Spira A,Stock W,Tallman MS,Cruz HG,Boni J,Havenith KEG,Chao G,Feingold JM,Wuerthner J,Solh M

    更新日期：2020-08-01 00:00:00

  • Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases.

    abstract：:We report on the clinico-biological characteristics of 20 cases of gammadelta T cell large granular lymphocyte (LGL) leukemia. All the data were compared to that of 196 cases with alphabeta T cell subtype, which represents the majority of T cell LGL leukemias. Clinical findings were quite similar in the two groups reg...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.04.011

    authors： Bourgault-Rouxel AS,Loughran TP Jr,Zambello R,Epling-Burnette PK,Semenzato G,Donadieu J,Amiot L,Fest T,Lamy T

    更新日期：2008-01-01 00:00:00

  • HL-R5 and HL-D4: two differentiation resistant HL-60 variants.

    abstract：:A wide range of different agents are capable of inducing the onset of HL-60 differentiation along the myeloid lineage. The diversity of these agents has made the analysis of the molecular mechanisms involved in the regulation of the onset and progress of terminal differentiation in these cells difficult. We have adapt...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(89)90081-7

    authors： Darling DC,Linskens MH,Farzaneh F

    更新日期：1989-01-01 00:00:00

  • High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission.

    abstract：:We evaluated outcomes in two consecutive groups of AML patients age>60 years in CR after 7+3 induction therapy. Group 1 received consolidation with cytarabine 1.5g/m(2) q12h×6+daunorubicin for two cycles, while group 2 received consolidation with 7+3 followed by mitoxantrone+etoposide. For patients with intermediate-r...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.leukres.2013.01.001

    authors： Hassanein M,Atenafu EG,Schuh AC,Yee KW,Minden MD,Schimmer AD,Gupta V,Brandwein JM

    更新日期：2013-05-01 00:00:00

  • Imatinib mesylate (IM)-induced growth inhibition is associated with production of spliced osteocalcin-mRNA in cell lines.

    abstract：:It has been suggested that imatinib mesylate (IM) influences osteogenesis and bone turnover in treated patients. Here we show that the inhibitory effect of IM on cell multiplication is associated with an increased proportion of spliced osteocalcin (OCNs) in leukemia (HL-60) and osteosarcoma cells (MG-63, U-2 OS), desp...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2007.07.020

    authors： Wihlidal P,Karlic H,Pfeilstöcker M,Klaushofer K,Varga F

    更新日期：2008-03-01 00:00:00

  • Effect of pulsed magnetic fields on leukemia-prone AKR mice. No-effect on mortality through five generations.

    abstract：:Leukemia-prone AKR mice were exposed twice a week to a 6 mT, 12 Hz or 460 Hz pulsed magnetic field for 30 min. If we take into account the five consecutive generations of mice, the above exposure actually took place in utero and, or during their life span. There was no difference in the incidence of leukemia or in the...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90165-p

    authors： Bellossi A

    更新日期：1991-01-01 00:00:00

  • Clinico-pathological characteristics of myeloid sarcoma at diagnosis and during follow-up: report of 12 cases from a single institution.

    abstract：:The aim of this study was to describe the presenting features, the frequency and outcome of myeloid sarcoma (MS) diagnosed in our Institution from January 1995 to December 2000. Twelve MS were seen and the frequency account for only 2% of all acute myeloid leukemia (AML) patients observed in our department in the same...

    journal_title：Leukemia research

    pub_type： 杂志文章,评审

    doi：10.1016/j.leukres.2004.01.022

    authors： Breccia M,Mandelli F,Petti MC,D'Andrea M,Pescarmona E,Pileri SA,Carmosino I,Russo E,De Fabritiis P,Alimena G

    更新日期：2004-11-01 00:00:00

  • Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.

    abstract：:Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse reactions were studied. In a total of 49 patients, the MEP regime...

    journal_title：Leukemia research

    pub_type： 临床试验,杂志文章

    doi：10.1016/s0145-2126(01)00114-x

    authors： Murohashi I,Kashimura T,Tominaga K,Wakao D,Takahashi T,Akiba M,Kishimoto K,Yoshida K,Yagasaki F,Itoh Y,Sakata T,Kawai N,Itoh K,Suzuki T,Matsuda A,Hirashima K,Bessho M

    更新日期：2002-03-01 00:00:00

  • Long-term follow-up of intensive ara-C-based chemotherapy followed by bone marrow transplantation for adult acute lymphoblastic leukemia: impact of induction Ara-C dose and post-remission therapy.

    abstract：:We report single institution outcome of brief, intensive ara-C-based chemotherapy using bone marrow transplantation as primary intensification for untreated adult patients with acute lymphoblastic leukemia (ALL). Overall disease-free and overall survival were inferior to those reported with prolonged chemotherapy mode...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/s0145-2126(01)00175-8

    authors： Sotomayor EM,Piantadosi S,Miller CB,Karp JE,Jones RJ,Rowley SD,Kaufmann SH,Braine H,Burke PJ,Gore SD

    更新日期：2002-05-01 00:00:00

  • Alterations of HLe-1 (T200) fluorescence intensity on acute lymphoblastic leukemia cells may relate to therapeutic outcome.

    abstract：:Quantitative differences in HLe-1 expression were studied on normal lymphocytes and lymphoblasts of patients with acute lymphoblastic leukemia (ALL). A relationship was found between quantitative antigen expression and therapeutic outcome. Alterations in fluorescence intensity (FI) were demonstrated using quantitative...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(87)90110-x

    authors： Caldwell CW,Patterson WP,Hakami N

    更新日期：1987-01-01 00:00:00

  • Serum erythropoietin concentrations in patients with myelodysplastic syndromes.

    abstract：:Medullary dyserythropoiesis with reduced production of erythrocytes is an early and consistent feature of myelodysplastic syndromes (MDS). The mechanism underlying the disturbed red cell proliferation and maturation is presently unknown. In order to study the role of erythropoietic growth factors, we determined by rad...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/0145-2126(91)90025-o

    authors： Aul C,Arning M,Runde V,Schneider W

    更新日期：1991-01-01 00:00:00

  • Simultaneous expression of CD13, CD22 and CD25 is related to the expression of Fc epsilon R1 in non-lymphoid leukemia.

    abstract：:Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the ex...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2003.10.034

    authors： Sato N,Kishi K,Toba K,Watanabe K,Itoh H,Narita M,Takahashi M,Aizawa Y

    更新日期：2004-07-01 00:00:00

  • In vivo efficacy of griseofulvin against multiple myeloma.

    abstract：:We recently confirmed that ciclopirox olamine inhibits Wnt/beta catenin signalling in myeloma. Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine. In this study the anti-tumor effect of GF was investigated. GF demonstrated a major apoptotic activity in various human and murine myeloma an...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2010.10.008

    authors： Kim Y,Alpmann P,Blaum-Feder S,Krämer S,Endo T,Lu D,Carson D,Schmidt-Wolf IG

    更新日期：2011-08-01 00:00:00

  • Possibility of myelodysplastic syndromes screening using a complete blood automated cell count.

    abstract：:Diagnosis of MDS has changed during the last years because of the 2008 WHO classification. Complete blood cell count (CBC) is a very important tool both for diagnosis of MDS. The aim of this study was to evaluate if it is possible to use the abnormal signals produced by dysplastic cells to produce a flag "dysplasia" a...

    journal_title：Leukemia research

    pub_type： 杂志文章

    doi：10.1016/j.leukres.2011.06.015

    authors： Rocco V,Maconi M,Gioia M,Silvestri MG,Tanca D,Catalano T,Avino D,Di Palma A,Rovetti A,Danise P

    更新日期：2011-12-01 00:00:00